Pathogen: SARS-CoV-2

PanoramicNOR

Norway
|
2023-2026
  • Adults (18-64 years)
  • General population
  • SARS-CoV-2
  • Post COVID-19 condition
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir

Peghetti

Italy
|
2021-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post COVID-19 condition
  • Non pharmacological intervention
  • Rehabilitation

PHOSP-COVID

United Kingdom
|
2020
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post COVID-19 condition

Plaza

Spain
|
2023-2025
  • Adults (18-64 years)
  • General population
  • SARS-CoV-2
  • Post COVID-19 condition
  • Non pharmacological intervention
  • Rehabilitation

LongCoCid

Germany
|
2022
  • General population
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition

Long-Neuro-COVID-19

Germany
|
2020-2024
  • Adults (18-64 years)
  • General population
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition

López-González

Spain
|
2021
  • Adults (18-64 years)
  • General population
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post COVID-19 condition

LoTECA

Norway
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Adolescents (12-17 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition

LUNGTERMcov

Switzerland
|
2021-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • Intensive care unit
  • SARS-CoV-2
  • Post COVID-19 condition

Matias-Guiu

Spain
|
2023-2024
  • Adults (18-64 years)
  • General population
  • SARS-CoV-2
  • Post COVID-19 condition
  • Non pharmacological intervention
  • Rehabilitation

Mazzitelli

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

Mazzitelli 2

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Remdesivir